Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Solid Biosciences Inc’s stock clocked out at $5.7, up 0.18% from its previous closing price of $5.69. In other words, the price has increased by $0.18 from its previous closing price. On the day, 0.79 million shares were traded. SLDB stock price reached its highest trading level at $5.85 during the session, while it also had its lowest trading level at $5.6.
Ratios:
To gain a deeper understanding of SLDB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.74 and its Current Ratio is at 6.74. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Needham on December 04, 2025, initiated with a Buy rating and assigned the stock a target price of $16.
On June 26, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $14.
On January 08, 2025, Truist started tracking the stock assigning a Buy rating and target price of $16.Truist initiated its Buy rating on January 08, 2025, with a $16 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’25 when Howton David T sold 4,932 shares for $5.11 per share. The transaction valued at 25,203 led to the insider holds 32,908 shares of the business.
Cumbo Alexander sold 10,808 shares of SLDB for $55,229 on Dec 03 ’25. The President and CEO now owns 81,388 shares after completing the transaction at $5.11 per share. On Dec 03 ’25, another insider, Hanrahan Jessie, who serves as the Chief Regulatory Officer of the company, sold 4,483 shares for $5.11 each. As a result, the insider received 22,908 and left with 26,660 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLDB now has a Market Capitalization of 444088352 and an Enterprise Value of 229883360.
Stock Price History:
The Beta on a monthly basis for SLDB is 2.69, which has changed by 0.45897436 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, SLDB has reached a high of $7.37, while it has fallen to a 52-week low of $2.41. The 50-Day Moving Average of the stock is 8.19%, while the 200-Day Moving Average is calculated to be 15.74%.
Shares Statistics:
It appears that SLDB traded 1.07M shares on average per day over the past three months and 920970 shares per day over the past ten days. A total of 77.88M shares are outstanding, with a floating share count of 58.88M. Insiders hold about 24.42% of the company’s shares, while institutions hold 82.76% stake in the company. Shares short for SLDB as of 1765756800 were 9943886 with a Short Ratio of 9.28, compared to 1763078400 on 9552193. Therefore, it implies a Short% of Shares Outstanding of 9943886 and a Short% of Float of 15.17.
Earnings Estimates
The stock of Solid Biosciences Inc (SLDB) is currently in the spotlight, with 13.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.39 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.84 and -$2.93 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$2.01, with 12.0 analysts recommending between -$1.49 and -$2.85.
